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Abstract
Background: A promoter polymorphism in the pro-inflammatory cytokine tumor necrosis factor (TNF)( TNF G-308A) is
associated with increased non-Hodgkin lymphoma (NHL) risk. The protein product, TNF-a, activates the nuclear factor kappa
beta (NF-kB) transcription factor, and is critical for inflammatory and apoptotic responses in cancer progression. We
hypothesized that the TNF and NF-kB pathways are important for NHL and that gene variations across the pathways may
alter NHL risk.
Methodology/Principal Findings: We genotyped 500 tag single nucleotide polymorphisms (SNPs) from 48 candidate gene
regions (defined as 20 kb 59,1 0k b3 9) in the TNF and TNF receptor superfamilies and the NF-kB and related transcription
factors, in 1946 NHL cases and 1808 controls pooled from three independent population-based case-control studies. We
obtaineded a gene region-level summary of association by computing the minimum p-value (‘‘minP test’’). We used logistic
regression to compute odds ratios and 95% confidence intervals for NHL and four major NHL subtypes in relation to SNP
genotypes and haplotypes. For NHL, the tail strength statistic supported an overall relationship between the TNF/NF-kB
pathway and NHL (p=0.02). We confirmed the association between TNF/LTA on chromosome 6p21.3 with NHL and found
the LTA rs2844484 SNP most significantly and specifically associated with the major subtype, diffuse large B-cell lymphoma
(DLBCL) (p-trend=0.001). We also implicated for the first time, variants in NFKBIL1 on chromosome 6p21.3, associated with
NHL. Other gene regions identified as statistically significantly associated with NHL included FAS, IRF4, TNFSF13B, TANK,
TNFSF7 and TNFRSF13C. Accordingly, the single most significant SNPs associated with NHL were FAS rs4934436 (p-
trend=0.0024), IRF4 rs12211228 (p-trend=0.0026), TNFSF13B rs2582869 (p-trend=0.0055), TANK rs1921310 (p-
trend=0.0025), TNFSF7 rs16994592 (p-trend=0.0024), and TNFRSF13C rs6002551 (p-trend=0.0074). All associations were
consistent in each study with no apparent specificity for NHL subtype.
Conclusions/Significance: Our results provide consistent evidence that variation in the TNF superfamily of genes and
specifically within chromosome 6p21.3 impacts lymphomagenesis. Further characterization of these susceptibility loci and
identification of functional variants are warranted.
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There is now convincing evidence that a promoter polymor-
phism in the pro-inflammatory cytokine tumor necrosis factor
(TNF)( TNF G-308A) is associated with increased risk for non-
Hodgkin lymphoma (NHL) and specifically with the NHL
subtype, diffuse large B-cell lymphoma (DLBCL) [1,2]. Further
evaluation of genetic variations in TNF and lymphotoxin-alpha
(LTA), the two prototypic genes that form the TNF superfamily,
suggest a role for additional polymorphisms in NHL risk [3] and
support the general importance of this genetic region in NHL and
DLBCL risk. There is also preliminary but growing evidence that
other genetic variants within the TNF and TNF receptor (TNFR)
superfamilies affect NHL risk [4–6].
The TNF gene product, TNF-alpha (TNF-a), is a proinflam-
matory cytokine involved in a number of biochemical pathways,
including the activation of the nuclear factor kappa beta (NF-kB)
transcription factor. NF-kB acts in two ways that are relevant for
lymphomagenesis. First, it has anti-apoptotic properties and
prevents cell death among cells with malignant potential. Second,
NF-kB stimulates the immune response, specifically the produc-
tion of pro-inflammatory cytokines, which permits survival and
proliferation of these cells [7]. These roles are supported by mouse
models that implicate both NF-kB and TNF-a in tumor
promotion [8,9].
Constitutive NF-kB expression characterizes a number of
lymphomas [10]. It is a hallmark of the activated B-cell like
(ABC) DLBCL [11,12], primary mediastinal B-cell lymphomas
(PMBLs), primary effusion lymphoma (PEL) [13,14], and mucosa-
associated lymphoid tissue (MALT) lymphoma [15]. NF-kB is also
constitutively expressed in Hodgkin lymphoma (HL) cell lines.
Human lymphomagenic viruses including the Epstein Barr Virus
(EBV), Kaposi sarcoma–associated herpesvirus (KSHV), and
human T-lymphotropic virus type I (HTLV-1) also carry NF-
kB–activating oncoproteins. As KSHV is a cause of primary
effusion lymphoma and HTLV-1 infection causes adult T-cell
lymphoma/leukemia, it is not surprising that both lymphomas also
have high levels of NF-kB activity [16].
TNF and LTA form the foundation of the TNF superfamily, a
family of homologous genes involved in NF-kB-mediated cellular
proliferation, apoptosis, survival and cell differentiation. To our
knowledge, there are no published reports specifically targeted at
extensive coverage of TNF or NF-kB genetic variations and NHL
risk.
To address this gap in knowledge, we conducted a pooled
analysis comprising three independent population-based case-
control studies of NHL to investigate the etiologic relevance of
common genetic variations in 48 genes (500 SNPs) encoding
important members of the TNF and TNF receptor (TNFR)
superfamilies, and NF-kB and related transcription factors, and I-
kappa-B proteins and kinases critical for NF-kB activation and
mediating its inhibition [7,17,18]. Gene families and regions
evaluated are denoted in Table 1 and extensively annotated in
Supplemental Materials (Tables S1 and S2).
Results
Descriptive characteristics of the 1,946 cases and 1,808 controls
by study are provided in Supplemental Materials (Table S3). The
distributions of cases and controls were similar with respect to age
and race/ethnicity. We note that our pooled population largely
comprised non-Hispanic Caucasians (87% of controls, 90% of
cases). The National Cancer Institute-Surveillance, Epidemiology,
and End Results (NCI-SEER) and Connecticut studies had similar
distributions of NHL subtypes, while the New South Wales (NSW)
study had a higher frequency of follicular lymphoma (FL) and a
lower frequency of chronic lymphocytic leukemia (CLL)/small
lymphocytic lymphoma (SLL) and NHL not otherwise specified
(NOS), compared to the other two studies.
Pathway- and gene region-based associations
We first assessed the overall strength of association between all
genes in the TNF and NF-kB family of genes with NHL and NHL
subtypes by measuring the tail strength statistic, as described in the
Methods Section. For NHL and all four subtypes, the tail strength
statistics were positive with the most notable tail strength statistic
observed for all NHL (p=0.02), supporting the overall relationship
between the TNF/NF-kB pathway and NHL (Table 2).
We focus our remaining discussion on eight selected gene
regions where the significance levels were ,0.05 by minP test or
likelihood ratio test, for all NHL. Briefly, as defined in the
Methods section, the minP test provides a gene region-level
summary of association by assessing statistical significance of the
smallest p-trend within each gene region by permutation-based
resampling methods and automatically adjusts for the number of
tag SNPs tested within that gene region and the underlying linkage
disequilibrium pattern. The likelihood ratio test is a complemen-
tary test that assesses the relative improvement in model fit from
the inclusion of parameters for all independent SNPs in a
particular gene region, thus determining if that region might still
be implicated in NHL risk despite no apparent significant SNP
association. Six of the gene regions (FAS, IRF4, TNFSF13B, TANK,
Table 1. Gene families and regions of analyzed candidate genes in three independent NHL case-control studies.
Gene family (of 500 SNPs) Gene regions*
TNF and TNF superfamily (n=122) LTA/TNF, TNFSF4, TNFSF7, TNFSF8, TNFSF9, TNFSF10, TNFSF12, TNFSF13B, TNFSF14, TNFSF18,
TNF receptors (TNFR) and TNFR superfamily (n=146) TNFRSF1A/LTBR/TNFRSF7, TNFRSF8/TNFRSF1B, TNFRSF9, TRFRSF12A, TNFRSF13B, TNFRSF13C,
TNFRSF14, TNFRSF17, CD40, TRADD
Death receptors (n=63) TNFRSF10B/TNFRSF10C/TNFRSF10D, TNFRSF10A, TNFRSF25
Fas (n=44) FAS, FASL, FADD, CFLAR
TRAF family (n=28) TRAF2, TRAF5, TRAF6, TANK
NFKB complex and transcription factors (n=51) NFKB1, NFKB2, REL, RELA, RELB, IRF4
I-kappa-B proteins and kinases (n=47) CHUK, IKBKB, NFKBIA, NFKBIE, NFRKB
Detailed annotation of genes and SNPs shown in Supplemental Materials (Tables S2 and S3).
*Gene regions defined as 20 kb 59 and 10 kb 39 of target gene.
doi:10.1371/journal.pone.0005360.t001
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PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5360TNFRSF13C, and TNFSF7) were significant at p,0.05 for all NHL
by both the minP test and likelihood ratio test; two (LTA/TNF and
NFKBIE) were significant by likelihood ratio test only. We note
that six of the eight gene regions selected are within the TNF or
TNF receptor (TNFR) superfamilies.
In gene region-based analyses by NHL subtype, we found
DLBCL associated with gene variants in the TNF superfamily
(TNFSF13B, LTA/TNF and TNFSF7) (Table 2). Other notable
subtype-specific associations include FAS and follicular lymphoma
(minP=0.006) and TNFSF13B and CLL/SLL (minP=0.001).
Results were generally consistent between the permutation test (p)
and likelihood ratio test (global p); results from both tests for all
genes are shown in Supplemental Materials (Table S4).
Association by SNPs
Consistentwithourgeneregion-basedanalyses,wefoundevidence
of an altered risk for one or more SNPs in FAS, IRF4, TNFSF13B,
TNFRSF13C,TANK,a n dTNFSF7, for all NHL(Table 2).Among the
SNPs with the minimum p value for each gene region, the
associations as evaluated using the additive model were consistent
across all three independent NHL studies (Figure 1) and were
statistically significant for one or more of the most common subtypes
(Figure 2). Most associations were found to be statistically significant
in at least one of the three studies (e.g., LTA, FAS, C22ORF13/
TNFRSF13C) and some in two of three studies (e.g., IRF4, TANK).
The p-trends for each gene variant contributing the minimum p are
shown in Figure 1 and ranges from 0.002 to 0.007.
In general, the SNP-based associations were in the same
direction for all four subtypes and the calculated p-heterogeneity
by the four subtypes was not statistically significant for any SNP
(Figure 2). We note that statistically significant associations with
DLBCL were observed for SNPs in TNFSF13B, LTA/TNF,
TNFSF7, FAS and IRF4. In addition, TNFSF7, TNFSF13B and
FAS were also significantly or marginally significantly associated
with follicular lymphoma. Finally, though TANK and C22ORB18/
TNFRSF13C were both statistically significantly associated with
follicular and marginal zone only, their associations were in the
same direction as for DLBCL and CLL/SLL.
Results for all SNPs and NHL, pooled, by study, and by NHL
subtypes are shown in Supplemental Materials (Tables S5 and S6).
Haplotype associations
Results from haplotype-based analyses (defined by blocks of
linkage disequilibrium) were generally consistent with the gene
region- and SNP-based findings (data not shown). However,
evaluation of the TNFSF13B and TNF/LTA regions, using a
sliding window approach of three loci, suggested new evidence of
association for regions not previously implicated with NHL risk in
the SNP-based analyses alone. Briefly, evaluation of the
TNFSF13B region yielded a new region comprising TNFSF13B
[rs8181791–rs16972216–rs17499386] significantly associated with
NHL (p=0.0025) not originally found significant by SNP-based
analysis and not in linkage disequilibrium with the already
implicated SNP, TNFSF13B rs2582869 (Figure S1).
Of the 16 polymorphisms we evaluated in the TNF/LTA region
on chromosome 6p21.3 which included the genes TNF, LTA and
NFKBIL1, a number of SNPs were associated with NHL, DLBCL,
and marginal zone lymphoma. Evaluation of the region using a
sliding window of three loci revealed the NFKBIL1 region to also
be significantly associated with NHL, including follicular lympho-
ma. The previously unidentified SNPs that comprise the NFKBIL1
haplotype [rs2857605–rs2239707–rs2230365] were most signifi-
cantly associated with NHL risk (p=0.0005) (Figure S2).
Discussion
In our pooled analysis of three predominantly Caucasian
studies, we found our set of candidate TNF and NF-kB family of
genes to be statistically significantly associated with NHL risk
when assessed globally as a pathway. Within the pathway, we
found that gene variants largely in the TNF superfamily were
associated with NHL, but that there were limited associations with
NHL for genetic variation in the NF-kB genes. Specifically, we
confirm that genetic variants in TNF/LTA (encoding for the
proinflammatory cytokines TNF-a and LT-a) were most pro-
nounced for DLBCL and marginal zone lymphoma. We further
provide new evidence using haplotype analysis that additional
variants in chromosome 6p21.3 (NFKBIL1-encoding IKBL1 and
thought to be a negative regulator of NF-kappa-B activation) may
be important for NHL risk, thus further implicating this
chromosomal region in which the search for causal SNPs should
be pursued. All other associations reported were in general
consistent across all four subtypes evaluated.
A major strength of the present study is the inclusion of data
from three independent population-based studies. By pooling these
studies, we achieved a sample size providing reasonable power to
detect moderate SNP effects, explore subtype specificity and most
importantly, evaluate the consistency of results between studies.
To our knowledge, the present analysis is the largest evaluation to
date specifically evaluating the role of the TNF/NF-kB pathway in
NHL risk. We note that our results are consistent when restricted
to non-Hispanic Caucasians and thus are unlikely to be biased by
population stratification. We acknowledge that some of our
findings may be false positive. However, consistency of association
across the three studies was a key criterion for identifying our
strongest findings, thus reducing this possibility. Nevertheless, our
results require replication in other independent populations and
further investigation to identify causal variants for NHL risk.
In addition to the confirmation of the TNF/LTA locus as
important for DBLCL risk, examination of the related NFKBIL1
gene on chromosome 6p21.3 revealed intriguing results. Though
its function remains unknown, it lies near TNF and at the
telomeric end of the major histocompatibility complex. Moreover,
it is a known susceptibility locus for rheumatoid arthritis [19].
Coupled with the known associations between TNF/LTA gene
variants with DLBCL risk, NFKBIL1’s location on 6p21.3 further
implicates this region in NHL risk. Notably, the NFKBIL1
haplotype is not correlated with the TNF/LTA SNPs and supports
that a causal SNP for NHL is located in this region. A further
detailed examination of this region is thus also warranted based on
our haplotype analysis.
All other implicated genes play critical roles in mediating
autoimmunity. Protein products of FAS, TNFSF13B (BAFF),
TNFRSF13C (BAFF-R), TNF and LTA can all activate the NF-kB
pathway, while TANK (encodes the TANK protein in the
cytoplasm and inhibits TRAF function) mediates the pathway
indirectly. Briefly, FAS (encodes the Fas receptor and binds to the
Fas ligand) is a prototypical death receptor and induces caspase-
dependent cell death and production of proinflammatory
cytokines including TNF-alpha [20,21]. Fas-deficient mice develop
elevated levels of serum autoantibodies and B cell plasmacytoid
lymphomas. Patients with autoimmune lymphoproliferative syn-
drome or ALPS have Fas mutations and are at high risk for NHL
[22]. TNFSF13B (encodes the cytokine BAFF) and its main
receptor BAFF-R (encoded by TNFRSF13C) play a central role in
peripheral B-cell survival and maturation, including inducing class
switch recombination. Altered BAFF expression is associated with
autoimmune conditions, B-cell lymphomas and immunodeficiency
TNF/NFKB Gene Variants and NHL
PLoS ONE | www.plosone.org 4 April 2009 | Volume 4 | Issue 4 | e5360[23]. BAFF and BAFF-R knock-out mice have B cells with
impaired survival while mice with overexpression of Baff develop
mature B-cell hyperplasia, follicular lymphoma, marginal zone
lymphoma and symptoms of systemic lupus erythematosus.
Immunodeficient mice express a naturally mutated form of
BAFF-R [24]. In humans, overexpression of the BAFF protein is
found in systemic lupus erythamatosus, rheumatoid arthritis and
Sjogren’s syndrome, all known risk factors for NHL. Human
NHL, CLL and Waldenstrom’s macroglobulinaemia B cells also
express BAFF-R [25]. In clinical studies, BAFFR-Ig has been
shown to inhibit myeloma cell groth in both in vivo (cell culture)
and ex vivo (mice) models [26]; further, a fusion toxin has been
developed for BLyS receptors such as BAFF-R with cytotoxic
effects inhibited when pretreated with soluble BAFF-R decoy
receptors [27] A SNP in the promoter of BAFF (-871C-.T,
rs9514827) was previously associated with increased BAFF
transcription and the -871T allele was more prevalent in familial
CLL patients compared to controls [28]. Though we did not
evaluate this SNP, we note that the global test of this gene region
was most strongly associated with CLL/SLL. Our results are thus
Figure 1. Odds ratios, 95% confidence intervals of additive model for SNPs with p-trends,0.01 for NHL in pooled analyses; data
also shown by study (adjusted for age, sex, race, and study site, when applicable). Data for all SNPs (pooled and by study) are shown in
Supplemental Materials (Table S5).
doi:10.1371/journal.pone.0005360.g001
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PLoS ONE | www.plosone.org 5 April 2009 | Volume 4 | Issue 4 | e5360consistent with other reports supporting a role for BAFF and its
main receptor, BAFF-R, as a susceptibility locus for NHL risk.
Our results showing a lack of association for several key NF-kB
genes (CHUK, which encodes a component of a protein complex
that inhibits NF-kB; IKBKB, which encodes a protein that is part of
the IKK complex and phosphorylates NF-kB inhibitors; and REL,
a proto-oncogene that encodes the transcription factor c-Rel and
binds the NFKB inhibitor) are consistent with a recent study,
although we were not able to replicate an association with NFKB1,
which encodes a pleiotropic transcription factor, reported in that
study [6].
Among NF-kB induced genes, we identified IRF4, a transcrip-
tional activator that binds to the MHC class I promoter and
immunoglobulin lambda light chain enhancer, as relevant for
NHL risk. IRF4 is critical for class switch recombination and
antibody maturation [29]. Its expression disables germinal center
formation by binding to and thus repressing BCL6 [30–33]. IRF4
knock-out mice are unable to mount antibody or antitumor
responses. Although high levels of IRF4 expression (and
constitutive NF-kB activation) have been reported specifically for
the activated B-cell subtype of DLBCL, our results suggest that
common variations in IRF4 may also influence risk for CLL/SLL
Figure 2. Odds ratios, 95% confidence intervals of additive model for SNPs with p-trends,0.01 for NHL in pooled analyses; data
shown by NHL subtypes DLBCL, follicular, CLL/SLL and marginal zone lymphomas in pooled population (adjusted for age, sex,
race, and study site). Data for all SNPs by NHL subtype are shown in Supplemental Materials (Table S6).
doi:10.1371/journal.pone.0005360.g002
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IRF4 (rs872071) as a top hit for CLL, with risk alleles associated
with lower mRNA expression in a dose-dependent fashion in the
study [34]. Furthermore, in RNA-interference studies, IRF4
inhibition has been demonstrated to be toxic to myeloma cell
lines [35]; gene expression profiling also demonstrated IRF4 to
target MYC in activated B cells, providing further evidence that
aberrant IRF4 regulation is critical for B cell activation.[35]
Finally, though downregulation of IRF4 expression has been
reported in chronic myeloid leukemia and acute myeloid leukemia
patients, IRF4 levels appear to increase during good response to
IFN-alpha therapy [36].
In summary, we report consistent evidence in three population-
based case-control studies that common genetic variation in genes
involved in TNF signaling pathways with NHL risk. Our results
are consistent with mouse models that implicate NF-kB and TNF-
a in tumor promotion [8,9]. Further pursuit of functional and
causal SNPs within chromosome 6p21.3 and replication of our
results are warranted.
Materials and Methods
Study Population
Our study population was derived from pooling three
independent population-based case-control studies, which have
been described in detail previously: the National Cancer Institute-
Surveillance Epidemiology and End Results (NCI-SEER) NHL
Case-Control Study [37], the Connecticut NHL Case-Control
Study [38,39], and the New South Wales (NSW) NHL Case-
Control Study [40]. All three studies included first primary NHL
cases only, and population controls were frequency matched to
cases. The studies were approved by the Institutional Review
Boards of the NCI and each SEER center for the NCI-SEER
study; Yale University, the Connecticut Department of Public
Health, and the NCI for the Connecticut study; and all
participating institutions for the NSW study. All study participants
provided informed consent.
NHL Pathology Classification
In the NCI-SEER and NSW study, all cases were histologically
confirmed by the local diagnosing pathologist. In the NSW study,
an expert hematopathologist also reviewed the pathological
material centrally when she judged the diagnosis of NHL to be
,90% certain upon review of the original pathology reports
(including flow cytometry). In the Connecticut study, all cases were
confirmed by central review of diagnostic slides by two
independent expert hematopathologists.
For the pooled analyses, we evaluated NHL overall and specific
NHL subtypes, grouping cases according to the World Health
Organization classification [41] using the International Lympho-
ma Epidemiology Consortium (InterLymph) guidelines [42]. For
analyses by NHL subtype, we evaluated the four most common
subtypes: diffuse large B-cell lymphoma (DLBCL) (28%), follicular
lymphoma (28%), marginal zone lymphoma (8%), and chronic
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
(8%) (Table 2). We note that our studies primarily included SLL
rather than CLL cases because these diseases were not considered
the same entity until the WHO classification was introduced in
2001.
Laboratory Methods
Biological samples and DNA extraction. Study
participants who did not provide a biologic specimen, did not
have sufficient material for DNA extraction or sufficient DNA for
genotyping, or whose genotyped sex was discordant from the
questionnaire data were excluded from this analysis. Specifically,
for the NCI-SEER study, of 1231 cases (820 blood, 411 buccal
cell) and 992 controls (692 blood, 300 buccal cell) with
biospecimens, 1001 cases and 834 controls were genotyped. For
the Connecticut study, 436 of 486 cases and 517 of 578 controls
with bloods were genotyped. For the NSW study, 524 of 597 cases
and 474 of 525 controls with bloods were genotyped.
For the NCI-SEER study, DNA was extracted from blood clots
or buffy coats (BBI Biotech, Gaithersburg, MD) using Puregene
Autopure DNA extraction kits (Gentra Systems, Minneapolis,
MN), and from buccal cell samples by phenol-chloroform
extraction methods [43]. Genotype frequencies for individuals
who provided blood compared with buccal cells were equivalent
[44]. For the Connecticut study, DNA was extracted from the
blood samples using phenol-chloroform extraction methods. For
the NSW study, DNA was extracted from buffy coats using
Qiagen QIAampH DNA Blood Midi Kits by laboratory staff at the
Viral Epidemiology Section, SAIC-Frederick, NCI-Frederick.
Genotyping. Genotyping of tag SNPs from 48 candidate
gene regions involved in TNF/NF-kB pathway was conducted at
the NCI Core Genotyping Facility (Advanced Technology Center,
Gaithersburg, MD; http://snp500cancer.nci.nih.gov) [45] using a
custom-designed GoldenGate assay (Illumina, www.illumina.com).
The GoldenGate assay included a total of 1536 tag SNPs, thus this
analysis was conducted as part of a panel that also included SNPs
from candidate genes in other pathways. Tag SNPs were chosen
from the designable set of common SNPs (minor allele frequency
(MAF).5%) genotyped in the Caucasian (CEU) population
sample of the HapMap Project (Data Release 20/Phase II,
NCBI Build 35 assembly, dbSNPb125) using the software Tagzilla
(http://tagzilla.nci.nih.gov/), which implements a tagging
algorithm based on the pairwise binning method of Carlson et al.
[46]. For each original target gene, SNPs within the region
spanning 20 kb 59 of the start of transcription (exon 1) to 10 kb 39
of the end of the last exon were grouped using a binning threshold
of r
2.0.8 to define a gene region. When there were multiple
transcripts available for genes, only the primary transcript was
assessed.
Quality control (QC). We excluded tag SNPs that failed to
properly cluster or did not amplify. SNPs with low completion rate
(,90% of samples) were excluded by study (NCI-SEER blood
samples: N=1; NCI-SEER buccal cell samples: N=4). QC
duplicates and replicates from each study were genotyped, blinded
to laboratory personnel. SNPs with concordance ,95% in the
study-specific QC samples were excluded for that study (NCI-
SEER buccal cell samples: N=1). We also excluded samples with
a low completion rate (,90% of the full panel of 1536 tag SNPs;
NCI-SEER: 11 cases, 6 controls; Connecticut: 2 controls; NSW: 4
cases, 9 controls). We included in our pooled analyses, 9 candidate
SNPs previously genotyped and analyzed by Taqman assay in at
least two of the three studies and located within one of our 48
candidate genes.
Hardy–Weinberg equilibrium was evaluated among non-
Hispanic Caucasian controls (N=1578, 87% of the analytic
population) for the pooled study population and by study. SNPs
showing evidence of deviation from Hardy–Weinberg proportions
(p,0.0001) included FAS rs1051070, TNFSF13B rs1041569,
TNFSF10 rs2041693, TNFRSF8 rs11569835, NFKBIA
rs17103286, TNFRSF1B rs1061624, CD40 rs11569309,
TNFRSF13B rs7504096, and TNFRSF10C rs12545733. Though
our QC data did not suggest any obvious genotyping error and we
present their results, we note caution in interpretation of these
select results.
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from the TNF/NF-kB pathway (Table 1, Table S1). Specifically,
the TNF/NF-kB pathway comprised genes from TNF and the
TNF superfamily, TNF receptors (TNFR) and the TNFR
superfamily, the TNF receptor-associated factor family (TRAF),
the NFKB complex, transcription factors, and the NFKB related I-
Kappa-beta proteins (Table 1).
Final analytic population. The final pooled analytic study
population included 1,946 cases and 1,808 controls (NCI-SEER:
990 cases, 828 controls; Connecticut: 436 cases, 515 controls;
NSW: 520 cases, 465 controls) with data for 500 SNPs (491 tag
SNPs and 9 previously genotyped Taqman SNPs).
Statistical methods
Pathway-based analysis. We summarized the overall
evidence of association for the 500 SNPs with NHL or an NHL
subtype by using the ‘‘tail strength’’ statistic [47], a summary
measure for the departure of the observed p-value distribution from
their expected distribution under the global null hypothesis of no
association in the whole pathway (all 48 candidate gene regions in
this analysis). We assessed the significance of the tail strength
statistics by generating their null distributions by permutation-based
resampling of the data. Analyses were conducted using the
MATLAB Statistics Toolbox
TM 6.2 (The Mathworks, Inc.,
Natick, MA).
Gene region-based analyses. We obtained a gene region-
level summary of association using two methods. First, we
computed the minimum p-value (‘‘minP test’’), which assesses
the statistical significance of the smallest p-trend within each gene
region (determined by dichotomous logistic regression, comparing
NHL or NHL subtypes to controls) by permutation-based
resampling methods (10,000 permutations) that automatically
adjust for the number of tag SNPs tested within that gene and the
underlying linkage disequilibrium pattern [48,49]. To account for
multiple comparisons within the pathway (all 48 candidate gene
regions in this analysis), we applied the false discovery rate (FDR)
method of Benjamini and Hochberg [50] to the minP test
separately for NHL and each subtype.
We also conducted a likelihood ratio test, assessing the relative
improvement in model fit from the inclusion of parameters for all
independent SNPs (r
2,0.8 among controls) in a particular gene,
assuming a codominant model for each SNP. Unlike the minP test
which ascertains significance of a genetic region with NHL risk
based on the minimum p value after adjusting for the total number
of SNPs evaluated in the region, this second method was used to
determine if additional genetic regions might be implicated in
NHL risk despite no apparent significant SNP association.
SNP-based analyses. We calculated odds ratios (OR) and
95% confidence intervals (CI) estimating the relative risk of NHL
and NHL subtypes in relation to SNP genotype using dichotomous
and polytomous unconditional logistic regression models,
respectively. The homozygote of the most common allele in the
pooled study population was used as the referent group. Tests for
trend under the co-dominant model used a three-level ordinal
variable for each SNP (0=homozygote common,
1=heterozygote, 2=homozygote variant). All models were
adjusted for age, race/ethnicity, sex, and study center (categories
listed in Table 2). We conducted analyses restricted to non-
Hispanic Caucasians and stratified by age (,50, $50 years) and
sex to evaluate the consistency of our results by various
demographic groups. To evaluate the consistency of our results
by NHL subtype, we assessed heterogeneity among NHL subtypes
in the polytomous multivariate unconditional logistic regression
models using the Wald chi-square statistic. Analyses were
conducted using SAS version 9.1 (SAS Institute, Cary, NC).
Haplotype analyses. We conducted haplotype analyses
among non-Hispanic Caucasians using two methods. First, we
evaluated risk of NHL and NHL subtypes associated with
haplotypes defined by SNPs within a sliding window of three loci
across a gene (Haplo Stats, version 1.2.1, haplo.score.slide, http://
mayoresearch.mayo.edu/mayo/research/schaid_lab/software.cfm).
A global score statistic was used to summarize the evidence of
association of disease with the haplotypes for each window. Second,
we visualized haplotype structures using Haploview, version 3.11
[51] based on measures of pairwise linkage disequilibrium between
SNPs. For blocks of linkage disequilibrium, we obtained ORs and
95% CIs for the underlying haplotypes under the assumption of an
additive model (haplo.glm, minimum haplotype frequency 1%).
All haplotype analyses were adjusted for age, sex, and study
center.
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